## PATENT APPLICATION DOCKET NO.: 1802.1003-002 (formerly CIT98-01pA2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

Applicants:

09/085,820

Group Art Unit:

1646

Filed:

May 28, 1998

Examiner:

J. Andres

Title:

Artery- And Vein-Specific Proteins And Uses Therefor

Hai U. Wang, Zhoufeng Chen and David J. Anderson

CERTIFICATE OF MAILING					
I hereby certify that this correspondence is being deposited with the United					
States Postal Service with sufficient postage as First Class Mail in an envelope					
addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arthagton, VA					
22202					
on 3-19.02 Minde m Crewford					
Date Signature					
Linda M. Crawford					
Timed or printed name of parson cigning certificate					

## THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** PO Box 2327 Arlington, VA 22202 20231

nformation Disclosure Statement is submitted:				
under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)				
under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).				
under 37 CFR 1.97(c) together with either:				
[ ] a Statement under 37 CFR 1.97(e), as checked below, or				
[X] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	0			
under 37 CFR 1.97(d) together with:	98580			
[ ] a Statement under 37 CFR 1.97(e), as checked below, and	38 09(			
[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)	00000038 09085820			
under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapp (Filed after payment of issue fee)	9 03/28/2002 NAHMED1			
	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)  under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the nation stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including the continued Examination).  under 37 CFR 1.97(c) together with either:  [ ] a Statement under 37 CFR 1.97(e), as checked below, or  [X] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)  under 37 CFR 1.97(d) together with:  [ ] a \$180.00 fee under 37 CFR 1.97(e), as checked below, and  [ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)  under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapp			

Stat	ement (	nder 37 CFR 1.97(e)					
[ ]	any	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or					
[ ]	com knov in th	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
Stat	ement U	nder 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000					
[ ]	com was	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.					
[X]	Enc	Enclosed herewith is form PTO-1449:					
	[X]	Copies of the cited references AY2, AZ2 and AR3 are enclosed.					
	[]	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]					
	[ ]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.					
	[ ]	The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by:					
		[ ] the explanation provided on the attached sheet.					
		[ ] the explanation provided in the Specification.					
		[ ] submission of the enclosed International Search Report.					
		[ ] submission of the enclosed English-language version of a foreign Search Report					

the enclosed English language abstract.

[ ]

[ ]	Appli	plicant requests that the following non-published pending applications be considered:			
Examiner Initials	's				
	_	U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
	_	U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
	_	U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
		Examiner	Date	_	
	[]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.	
	[ ]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [	nt claims, is enclosed, except ], to which priority under	
The E	Examine nces we	er is requested to return a copy of ere considered with the next offic	the above list of pending ap e communication.	plications indicating which	
It is re	equestec	d that the information disclosed h	erein be made of record in the	his application.	
Metho	od of pa	yment:			
[X]	A che accon	cck for the fee noted above is encloped appropriate for the fee noted above is enclosed. A copy of this S	losed, or the fee has been incotatement is enclosed.	cluded in the check with the	
[ ]	Please	the charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is used.			
[X]	Please	e charge any deficiency in fees an	nd credit any overpayment to	Deposit Account 08-0380.	
		F	Respectfully submitted,		
		F	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.	
		E	Anne I Craig  Resistantian No. 32 076	<del></del>	
			Registration No.: 32,976 Telephone: (978) 341-036 Facsimile: (978) 341-0136		

Concord, MA 01742-9133 Dated: 3-19-02

ID NO.	: ::0	DMA\MHODMA\iManage;28		Sheet 1 of 1
PTO 1744	REPAC	DDUCED	ATTORNEY DOCKET NO. 1802.1003-002	APPLICATION NO. 09/085,820
MAR 2 5		MHIRD SUPPLEMENTAL STION DISCLOSURE CITATION N AN APPLICATION	APPLICANT Hai U. Wang, et al.	
Warra W	ADEMARY (Use	March 19, 2002 several sheets if necessary)	FILING DATE May 28, 1998	GROUP 1646
		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	Pages, Etc.)
/	AY2	Adams, R.H., et al., "Roles Cardiovascular Development: Vascular Morphogenesis, and 306 (1999).	s of EphrinB Ligands an : Demarcation of Arter d Sprouting Angiogenesi	d EphB Receptors in ial/Venous Domains, s," Genes Dev. 13:295-
	AZ2	Henkemeyer, M., et al., "Nu in the Mammalian Central Ne	uk Controls Pathfinding ervous System," Cell, 8	of Commissural Axons 6:35-46 (1996).
ĺ	AR3	Orioli, D., et al., "Sek4 a Commissural Axons and in Pa (1996).	and Nuk Receptors Coope alate Formation," Embo	rate in Guidance of J., 15(22):6035-6049
				H
				ST COMPANY
				〒25 円
				2002 1600

EXAMINER

DATE CONSIDERED